DDInter1934 DDInter1658
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Vilanterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexamethasone
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Vilanterol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Vilanterol {u} may lead to a major life threatening interaction when taken with {v} Carvedilol
Vilanterol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Vilanterol may lead to a major life threatening interaction when taken with Macimorelin
Vilanterol may lead to a major life threatening interaction when taken with Carvedilol